Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS Health

UnitedHealth Group

With the Federal Trade Commission (FTC) taking a scalpel to the pharmacy benefit managers (PBMs) of UnitedHealth Group Inc UNH, CVS Health Corp CVS and Cigna Group CI, investors are left wondering which health giant can best weather the storm.

UnitedHealth Vs. CVS Vs. Cigna: Which Health Stock Will Beat The FTC's Regulatory Heat?

Express Scripts was the first to cap out-of-pocket costs for insulin medications at $25 for a 30-day supply in 2019, well before the government took action ST. LOUIS , Sept.

Express Scripts Comments on FTC's Reckless Insulin Action

The FTC sued UnitedHealth Group's Optum unit, CVS Caremark and Cigna's Express Scripts for allegedly steering diabetes patients towards higher priced insulin.

UnitedHealth, CVS Caremark, Express Scripts sued by FTC over skyrocketing insulin prices

Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.

FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice'

Humana

The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to artificially inflate the cost of insulin.

Explainer: Why are US pharmacy benefit managers under fire?

The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen boost their profits while "artificially" inflating costs for patients.  The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts, and their affiliated group purchasing organizations.

FTC sues drug middlemen for allegedly inflating insulin prices

I am initiating a 'Buy' rating for Cigna with a one-year target price of $450 per share, driven by strong Specialty and Cigna Healthcare growth. Cigna's Specialty Pharmacy and Care Market, accounting for 30% of revenue, is poised for above-market growth due to its leadership in the chronic market and biosimilar offerings. Cigna Healthcare's divestiture of low-margin Medicare businesses will allow focus on employer-sponsored plans, targeting small and mid-size enterprises, contributing to 7% organic revenue growth.

Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'

As the telehealth sector is projected to reach $450 billion by 2032, Cigna Healthcare recently launched an “E-Treatment” option via MDLIVE, offering customers access to urgent care from board-certified doctors without the need for direct phone or video consultations.

Cigna Launches E-Treatment Service for Convenient Patient Access

Cigna Group's pharmacy benefit manager Express Scripts on Tuesday sued the U.S. Federal Trade Commission, alleging that the agency's July report on the PBM industry was biased and defamatory and asking the court to order the FTC to withdraw the report.

Cigna's PBM Express Scripts sues the FTC, seeking retraction of drug-cost report

FTC's July 2024 report makes unsubstantiated, false and biased claims about the PBM industry; fails to take into account the value that PBMs deliver to consumers and patients ST. LOUIS , Sept.

Express Scripts Sues FTC, Demands Withdrawal of PBM Report

One of the country's biggest pharmacy-benefit managers, Cigna Group's CI 0.58%increase; green up pointing triangle Express Scripts, sued the Federal Trade Commission, demanding a retraction of a recent report critical of the companies that negotiate drug spending.

Cigna Demands FTC Retraction in Escalating Drug-Price Fight

CI's new launch, a new E-Treatment option, is expected to improve patient satisfaction and operational efficiency.

Cigna's Health Benefits Unit Launches a New E-Treatment Option

BLOOMFIELD, Conn. , Sept. 12, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that Matt Perlberg, President of the Evernorth Health Services pharmacy and care delivery businesses, will present at the Bernstein Healthcare 1:1 Forum on September 24, 2024, in New York, NY.

The Cigna Group Announces Appearance at the Bernstein Healthcare 1:1 Forum

E-Treatment services powered through MDLIVE by Evernorth routinely deliver customers diagnoses and treatment plans within one hour without any direct interaction Now available to U.S. Cigna Healthcare customers who have coverage through the individual marketplace or their employer BLOOMFIELD, Conn. , Sept. 12, 2024 /PRNewswire/ -- Cigna Healthcare, the health benefits division of The Cigna Group (NYSE: CI), launched an "E-Treatment" option through MDLIVE by Evernorth.

Cigna Healthcare Makes Virtual Care Even Easier and More Convenient with New E-Treatment Option from MDLIVE

CI benefits from improved premiums resulting from an extensive customer base. Buyouts and adequate operating cash flows are other tailwinds.

Cigna Stock Gains 26% in a Year: What Lies Ahead for Investors?

As part of the company's initiative, thousands of employees logged 280,000 minutes of exercise over nine days Cigna leaders biked to Hartford, Conn.'s Dunkin' Park to host Boys & Girls Clubs members for a Yard Goats baseball game, with surprise appearances by UConn basketball coach and players BLOOMFIELD, Conn.

The Cigna Group's "Community Vitality Project" Donates $75,000 to Nonprofits through Program Encouraging Fitness and Community Engagement

LVMH Moet Hennessy Louis Vuitton

Target

Dividends are an investor's best friend. While it is a well-known fact the S&P 500 has returned on average 10.5% annually since its inception in 1957, less known is that dividends account for 85% of the index's cumulative total return.

If You Can Buy Only 1 Dividend Stock, Make It One of These 3 Income Stars

The Cigna Group (NYSE:CI ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 10:45 AM ET Company Participants David Cordani - Chairman and CEO Conference Call Participants Erin Wright - Morgan Stanely Erin Wright Good morning, everyone. Welcome to the Morgan Stanley Healthcare Conference.

The Cigna Group (CI) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Arch Capital

Everest Group Ltd

Diamondback Energy

General Motors

McCormick

Molina Healthcare

Principal Financial Group

PulteGroup

Universal Health Services

A narrowly focused screen of value stocks highlights stocks trading cheaply to book value, sales and earnings, but which are also expected to increase sales per share rapidly

10 ‘enhanced value' stocks of companies expected to grow quickly through 2026

Estimated to save individual Accredo patients around $4,000 per year Biosimilar price will be more than 80% lower than Stelara list price Accredo patients benefit from the specialty pharmacy's best-in-class clinical support BLOOMFIELD, Conn. , Sept. 5, 2024 /PRNewswire/ -- Evernorth Health Services announced that it plans to have a Stelara biosimilar available for $0 out of pocket for eligible patients of its specialty pharmacy, Accredo, beginning in early 2025.

Evernorth announces another step forward in lowering drug prices by making a Stelara biosimilar available at $0 out of pocket for patients early next year

Abbott Labs

Adobe

Allianz SE

Bank of Nova Scotia

Canadian National Railway Company

Enterprise Products Partners

Reckitt Benckiser Group PLC

Siemens AG

The economy is stable but cooling, with the labor market showing signs of slowing down. GDP growth is likely to keep falling, and individual companies could suffer. Long-term investors should focus on companies with strong risk management and adaptability to changing economic conditions, ensuring consistent returns and dividend growth. These 10 companies average an A-credit rating and S&P risk management in the top 0.4% of global companies.

10 High-Yield A-Rated Blue-Chips For Potentially Scary Times Ahead

JERSEY CITY, N.J. , Aug. 28, 2024 /PRNewswire/ -- Celltrion USA announced today that it has signed an agreement with Cigna Healthcare, the health benefits provider of the Cigna Group and Express Scripts, the pharmacy benefits services business of the Cigna Group's Evernorth and one of the nation's leading health insurers, that will help expand patient access to ZYMFENTRA® (infliximab-dyyb), the first and only U.S. Food and Drug Administration (FDA)-approved subcutaneous infliximab.

Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit formulary

AbbVie

Cigna said on Monday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead.

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Cigna (CI) is a Strong Momentum Stock

BLOOMFIELD, Conn., Aug. 15, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that David Cordani, Chairman and Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, in New York, NY.

News for Cigna Stock (CI)